Portfolio companies: Over 60 successful trade sales and IPOs

Pearls in a shell

Current portfolio companies 
Past portfolio companies

  • Acusphere, USA

    Drug development injectables

    Acusphere was listed on NASDAQ in 2003.

  • Adnexus Therapeutics, USA

    Antibody technology platform

    Adnexus was acquired by Bristol-Myers Squibb for $430 million in 2007.

  • Advanced Accelerator Applications, France

    Drug development oncology

    AAA was listed on NASDAQ in 2015, then acquired by Novartis for $3.9 billion in 2017.

  • Agensys, USA

    Antibody technology platform

    Agensys was acquired by Astellas for up to $537 million in 2007.

  • Allena Pharmaceuticals

    Kidney and metabolic disorders

    Allenawas listed on NASDAQ in 2017.

  • Alydia Health, USA

    Women's health

    Alydia was acquired by Organon for up to $240 million in 2021.

  • Anadys Pharmaceuticals, USA

    Drug development antivirals

    Anadys Pharmaceuticals was listed on NASDAQ in 2004.

  • AnaptysBio, USA

    Drug development inflammation

    AnaptysBio, Inc.  was listed on NASDAQ in 2017.

  • Anthera, USA

    Drug development cardiovascular

    Anthera was listed on NASDAQ in 2010. 

  • APR Applied Pharma Research

    Drug development and formulation

    APR Applied Pharma Research was acquired by Relief Therapeutics for CHF66.5M on Jun 29, 2021.

  • Aptinyx

    CNS diseases

    Aptinyx was listed on NASDAQ in 2018.

  • Arcutis Biotherapeutics

    Immune-mediated skin diseases

    Arcutis was listed on NASDAQ in 2020.

  • ARMO Biosciences, USA

    Drug development oncology

    ARMO Biosciences was acquired by Eli Lilly for 1.6 billion in May 2018 .

  • Arpida, Switzerland

    Drug development antibacterials

    Arpida was listed on SIX Swiss Exchange in 2005.

  • Aspreva, Canada

    Specialty pharma

    Aspreva was listed on NASDAQ in 2005 and acquired by Galenica in 2007 for $915 million.

  • Asthmatx, USA

    Medical device pulmonary diseases

    Asthmatx was sold to Boston Scientific for up to $443 million in 2010. 

  • Axovan, Switzerland

    Drug development cardiovascular

    Axovan was acquired by Actelion in 2004 for up to CHF252 million.

  • Barofold, USA

    Protein technology platform

    BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for biopharma companies and research institutions.

  • Basilea Pharmaceutica, Switzerland

    Drug development antibacterials and antifungals

    Basilea was listed on SIX Swiss Exchange in 2004.

  • BioAtla

    Oncology

    BioAtla was listed on NASDAQ in 2020.

  • BioControlMedical, Switzerland/Israel

    Medical device neurology

    BioControl Medical develops implantable medical devices to treat disorders of the autonomic nervous system.

  • Bioshin

    CNS diseases

    Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant

  • Biovitrum, Sweden

    Biopharmaceutical

    Biovitrum was listed on OMX Stockholm in 2006. In 2010 Biovitrum and Swedish Orphan merged forming Swedish Orphan Biovitrum.

  • Brahms, Germany

    Specialty diagnostics

    Brahms was acquired by ThermoFischer for $470 million in 2009.

  • C 4 Therapeutics, USA

    Targeted protein degradation

    C4 Therapeutics was listed on NASDAQ in 2020.

  • Cardion, Germany

    Drug discovery inflammation

    Cardion was acquired by Roche in 2003.

  • ChemoCentryx, USA

    Drug development inflammation

    ChemoCentryx was listed on NASDAQ in 2012.

  • China Nuokang, China

    Specialty pharma

    China Nuokang, China

  • Connect Biopharma

    Inflammatory Diseases

    Connect Biopharma was listed on NASDAQ in 2021.

  • Corgentech, USA

    Drug development cardiovascular

    Corgentech was listed on NASDAQ in 2004.

  • Corvidia Therapeutics, USA

    Drug development cardiovascular

    Corvidia was acquired by Novo Nordisk for up to $2.1 billion in 2020.

  • Curetis, Germany

    Diagnostics

    Curetis was listed on Euronext in 2015 and then merged with  NASDQ listed OpGen in 2019.

  • Cytokinetics, USA

    Drug development cardiovascular

    Cytokinetics was listed on NASDAQ in 2004.

  • Cytos Biotechnology, Switzerland

    Vaccine technology platform

    Cytos was listed on SIX Swiss Exchange in 2002.

  • Delenex Therapeutics, Switzerland

    Antibody technology platform

    Delenex was acquired by Cell Medica in 2016.

  • Eiger BioPharmaceuticals, USA

    Drug development orphan diseases

    Eiger BioPharmaceuticals was listed on NASDAQ in 2016.

  • Ellipse Technologies, USA

    Medical device orthopedic implants

    Ellipse Technologies was acquired by NuVasive (Nasdaq: NUVA) in 2016.

  • Enanta Pharmaceuticals, USA

    Infectious diseases

    Enanta was listed on NASDAQ in 2013.

  • Esbatech, Switzerland

    Drug development ophthalmology

    Esbatech was acquired by Alcon (Novartis) for up to $589 million. 

  • Everest Medicines

    Anti-Infectives; Oncology

    Everest Medicines was listed on the Hong Kong Stock Exchange in 2020.

  • Forbius, USA

    Drug development oncology

    Forbius was acquired by Bristol-Myers Squibb in 2020.

  • Galecto, Denmark/USA

    Fibrosis / Lung diseases

    Galecto was listed on NASDAQ in 2020.

  • Galera Therapeutics, USA

    Drug development oncology

    Galera was listed on NASDAQ in 2019.

  • Gemin X, Canada

    Drug development oncology

    Gemin X was acquired by Cephalon for $225 million in 2003.

  • Homology Medicines, USA

    Drug development genetic diseases

    Homology was listed on NASDAQ in 2018.

  • Hookipa Biotech

    Drug development oncology and autoimmune diseases

  • Icagen, USA

    Drug development inflammation

    Icagen was listed on NASDAQ in 2004.

  • Infinity Pharmaceuticals, USA

    Drug development oncology

    Infinity Pharmaceuticals was listed on NASDAQ in 2006. 

  • InstilBio

    Oncology

    InstilBio was listed on NASDAQ in 2021.

  • Interventional Spine, USA

    Percutaneous spine implants

    Interventional Spine was acquired DePuy Synthes in 2017.

  • iTeos Therapeutics

    Oncology

    iTeos was listed on NASDAQ in 2020.

  • Kolltan Pharmaceuticals, USA

    Drug development oncology

    Kolltan Pharmaceuticals was acquired by Celldex for up to $235 million.

  • Lifeline Scientific, USA

    Medical device transplantology

    Lifeline Scientific was listed on AIM London in 2008. 

  • Mediservice, Switzerland

    Drug distribution

    Mediservice was acquired by Galenica in 2007.

  • Micromet, Germany/USA

    Drug development oncology

    Micromet was listed on NASDAQ in 2003 and subsequently acquired by Amgen for $1.16 billion.

  • Micrus Endovascular, USA

    Medical device neurology

    Micrus was listed on NASDAQ in 2005 and acquired by J&J /DePuy in 2010.

  • Mpex, USA

    Drug development pulmonary diseases

    Mpex was acquired by Axcan in 2011.

  • mtm Laboratories, Germany

    Diagnostics cervical cancer

    mtm was acquired by Roche for up to EUR190 million in 2011. 

  • Nabriva, Austria

    Drug development antibacterials

    Nabriva was listed on NASDAQ in 2015.

  • Newron Pharmaceuticals, Italy

    Drug development neurology

    Newron was listed on SIX Swiss Exchange in 2006.

  • Northstar Neurosciences, USA

    Medical device neurology

    Northstar was listed on NASDAQ in 2006.

  • ObsEva, USA / Switzerland

    Women’s Health

    ObsEva was listed on NASDAQ in 2017.

  • Ophthotech, USA

    Drug development ophthalmology

    Ophthotech was listed on NASDAQ in 2013.

  • Panomics, USA

    Molecular biology platform

    Panomics was acquired by Affymetrix for $73 million in 2008.

  • Paratek Pharmaceuticals, USA

    Drug development antibacterials

    Paratek was listed on NASDAQ in 2014.

  • PharmaSwiss, Switzerland

    Specialty pharma

    PharmaSwiss was acquired by Valeant for EUR350 million in 2009. 

  • Precimed, Switzerland/USA

    Medical device surgical instruments

    Precimed was acquired by GreatBatch for $125 million in 2008.

  • Principia Biopharma, USA

    Oncology

    Principia was listed on NASDAQ in 2018, then acquired by  Sanofi for $3.7 billion in 2020.

  • Probiodrug, Germany

    Drug development alzheimer

    Probiodrug was listed on Euronext in 2014.

  • PTC

    Drug development orphan diseases

    PTC was listed on NASDAQ in 2013.

  • Pyxis Oncology

    Oncology

    Pyxis was listed on NASDAQ in 2021.

  • Renovis, USA

    Drug development neurology

    Renovis was listed on NASDAQ in 2003.

  • Seer Therapeutics, USA

    Proteomic analysis

    Seer was listed on NASDAQ in 2020.

  • Shriji Polymers Ltd

    Pharmaceutical packaging

    Secondary stake acquired by Creador Capital in 2020.

  • SkyePharma, U.K.

    Drug development respiratory diseases

    Merger with Vectura Group plc (LSE: VEC) in 2016.

  • Sloning BioTechnology, Germany

    DNA technology platform

    Sloning was acquired by Morphosys in 2010.

  • SpringWorks Therapeutics

    Oncology

    SpringWorks was listed on NASDAQ in 2019.

  • Sublimity Therapeutics

    Drug development

  • Sunesis Pharmaceuticals, USA

    Drug development oncology

    Sunesis was listed on NASDAQ in 2005.

  • Symbiomix Therapeutics, USA

    Drug development women’s health

    Symbiomix was acquired by Lupin for $150 million plus contingent payments in 2017.

  • Syntonix, USA

    Drug development rare blood diseases

    Syntonix was acquired by Biogen Idec for up to $120 million in 2007.

  • Syrrx, USA

    Drug discovery

    Syrrx was acquired by Takeda for $270 million in 2005.

  • TandemLife (CardiacAssist), USA

    Medical device cardiovascular

    TandemLife was acquired by LivaNova (Nasdaq:LIVN) for up to $250 million in 2018.

  • Tensys, USA

    Patient monitoring

    Assets of Tensys were acquired by a Chinese  Company by end of 2017. 

  • Transform Pharmaceuticals, USA

    Drug discovery

    Transform was acquired by Johnson & Johnson for $230 million in 2005.

  • True North Therapeutics, USA

    Drug development rare blood diseases

    True North Therapeutics was acquired by Bioverativ in 2017 for up to $825 million.

  • Turning Point Therapeutics

    Cancer targeted therapies

    Turning Point was acquired by Bristol Myers Squibb for $4.1 billion in 2022.

  • Viela Bio

    Autoimmune and severe inflammation

    Viela Bio was acquired by Horizon Therapeutics for $3 billion in 2021.

  • Vitaeris Inc., Canada

    Drug development immunology

    Vitaeris was acquired by CSL Behring in 2020.

  • Werewolf Therapeutics, USA

    Drug development oncology

    Werewolf was listed on NASDAQ in 2021.

  • Westmed, USA

    Anesthesia and respiratory products

    Westmed was acquired by a subsidiary of Sunmed Group Holdings LLC for approximately $75 million in 2020.

  • Xenoport, USA

    Drug development neurology

    Xenoport was listed on NASDAQ in 2005.

  • Ziemer, Switzerland

    Medical device ophthalmology

    Sale of position to an investor in 2009.

  • Zycos, USA

    Drug development antivirals

    Zycos was acquired by MGI Pharma for $50 million in 2004.